Filing Flows › Alpha Teknova (TKNO) › Q2 2026 › vs Q2 2025
Alpha Teknova (TKNO) Q2 2026 vs Q2 2025 (year over year)
Alpha Teknova's revenue rose $1.9M (+18%) from $10.3M in Q2 2025 to $12.2M in Q2 2026. The biggest changes: Lab Essentials +$1.4M (+18%); Clinical Solutions +$368K (+18%); Other Product +$138K (+32%).
Alpha Teknova, Q2 2026: revenue $12.2M (+18% year over year), operating margin -23.7%, net loss $3.2M, operating cash flow −$471K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Lab Essentials | $9.2M | $7.8M | $1.4M | +18% |
| Clinical Solutions | $2.4M | $2.1M | $368K | +18% |
| Other Product | $573K | $435K | $138K | +32% |
| Revenue | $12.2M | $10.3M | $1.9M | +18% |
| Net loss | $3.2M | $3.6M | −$400K | -11% |
| Costs & expenses | $15.4M | $13.9M | $1.5M | +11% |
| Operating costs | $15.1M | $13.7M | $1.4M | +10% |
| Interest & other, net | $250K | $165K | $85K | +52% |
| Income tax | $30K | $19K | $11K | +58% |
| Cost of revenue | $7.3M | $6.3M | $997K | +16% |
| Research & development | $554K | $581K | −$27K | -5% |
| Sales & marketing | $2.1M | $1.6M | $549K | +35% |
| General & admin | $4.8M | $4.9M | −$117K | -2% |
| Other operating costs | $287K | $287K | $0 | 0% |
| Operating cash sources | $3.2M | $3.6M | −$400K | -11% |
| Depreciation & amortization | $1.6M | $1.6M | $3K | +0.2% |
| Share-based compensation | $622K | $950K | −$328K | -35% |
| Working capital & other | $484K | −$1.1M | $1.6M | — |
| Cash used in operations | $471K | $2.1M | −$1.6M | -78% |
| Net loss absorbed | $3.2M | $3.6M | −$400K | -11% |
Questions
How much did Alpha Teknova's revenue grow year over year in Q2 2026?
Alpha Teknova's revenue rose $1.9M (+18%) from $10.3M in Q2 2025 to $12.2M in Q2 2026.
What drove Alpha Teknova's revenue change in Q2 2026?
Lab Essentials +$1.4M (+18%); Clinical Solutions +$368K (+18%); Other Product +$138K (+32%).